Medovex said today that it sold its 1st DenerveX system, and that the device had been used in its 1st commercial procedures since winning CE Mark approval in the European Union last month.
The DenerveX system uses a slowly rotating burr to remove targeted facet joint synovial membrane and radiofrequency ablation technology to destroy tissue and denude any residual nervous and synovial membrane on the joint, effectively removing sensory tissue from it, the Atlanta-based company said.
The system consists of a DenerveX device kit with a single use medical device and a DenerveX Pro-40 power generator, Medovex said.
“Our 1st human use cases for the DenerveX System which took place in Manchester, England recently with very encouraging initial procedural success. We anticipate performing up to as many as 30 plus additional procedures by the end of August. This is the beginning of delivering on our goal of ‘proof of principle’ in the adoption of the technology in this very sizable market. We are also pleased to have also reached our first revenue events in the EU with others soon to expected to follow,” CEO Jarrett Gorlin said in a press release.
“With the DenerveX System, we can offer surgeons and pain management specialists the ability to attain precise treatment of the facet joint pain. The DenerveX treatment uses ‘rotacapsulation,’ a combination of high heat and rotational capsular tissue shaving, in a minimally invasive posterior procedure for the treatment of Facet Joint Syndrome. The DenerveX System offers an alternative to existing treatments only providing temporary relief,” prez & COO Patrick Kullmann said in a prepared statement.
Medovex announced it had won CE Mark approval in the European Union for the device early last month.
